论文部分内容阅读
目的:用杂交瘤技术制备脐血树突状细胞(DC)和食管癌细胞的融合疫苗,观察其在体内外抗肿瘤的作用。方法:分离脐血CD34+干细胞并诱导扩增为成熟DC,并与EC109细胞经聚乙二醇法融合;免疫磁珠法筛选EC109-DC;MTT法测定瘤苗诱导淋巴细胞增殖能力及体外特异性免疫应答能力;重建SCID小鼠免疫功能;体内抗肿瘤免疫治疗实验。结果:(1)融合疫苗可体外生长,且同时高表达叶酸受体和CD80。(2)疫苗能有效刺激淋巴细胞增殖反应,体外诱导细胞毒T细胞(CTL)对EC109的杀伤活性显著高于对照组(P<0.05)。(3)在免疫治疗中,用融合瘤苗治疗的荷瘤小鼠,肿瘤大小和重量明显小于对照组(P<0.05)。结论:(1)EC109-DC能在体外刺激淋巴细胞增殖和诱导特异性CTL杀伤作用;(2)融合瘤苗治疗荷瘤小鼠有一定的效应。
OBJECTIVE: To prepare fusion vaccine of dendritic cells (DCs) and esophageal cancer cells by hybridoma technique and observe its antitumor activity in vitro and in vivo. Methods: Cord blood CD34 + stem cells were isolated and induced to proliferate into mature DCs. The EC109 cells were fused with EC109 cells by polyethylene glycol method. EC109-DCs were screened by immunomagnetic beads method. The ability of tumor cells to induce proliferation of lymphocytes and their in vitro specificity Immune response ability; reestablish immune function of SCID mice; in vivo anti-tumor immunotherapy experiment. Results: (1) The fusion vaccine can grow in vitro, and at the same time high expression of folate receptor and CD80. (2) The vaccine can effectively stimulate the proliferation of lymphocytes, and the killing activity of EC109 induced by cytotoxic T cells (CTL) in vitro was significantly higher than that of the control group (P <0.05). (3) In the immunotherapy, tumor-bearing mice treated with the fusion tumor vaccine had significantly smaller tumor size and weight than the control group (P <0.05). Conclusion: (1) EC109-DC can stimulate the proliferation of lymphocytes in vitro and induce the specific CTL killing effect; (2) The fusion tumor vaccine has certain effect on tumor-bearing mice.